Multiple myeloma is the second most prevalent hematological malignancy, with over 55,000 new cases diagnosed each year. This exciting new text, edited by lauded authorities on the topic, stands as the only available reference to assemble, review, and synthesizes the latest studies on translational therapies and clearly explains the impact of molecular pathogenesis, biology, and prognostic factors on the diagnosis, prognosis, and individualization of treatment and the development of novel therapeutic options for patients with myeloma.
Moving from the bench to the bedside to the forefront of therapeutic development, this source:
- helps clinicians and researchers effectively deploy therapeutic strategies into clinical practice
- reflects trends in the use of agents which target both the tumor cell and its bone marrow microenvironment to overcome resistance to conventional therapies
- considers the critical role of the bone marrow microenvironment in the regulation of growth, survival, and homing of multiple myeloma
- discusses novel therapies in phase I and phase II trials, focusing specifically on therapeutic options for patients with newly diagnosed or relapsed/refractory multiple myeloma
- addresses novel therapies for other plasma cell disorders, and provides the framework for the design of next generation agents and combination therapies
- covers the entire scope of translational work in multiple myeloma, from advances in molecular pathogenesis, to prognostic factors, immunotherapy, and new options for newly diagnosed and relapsed multiple myeloma patients
Table of Contents
Molecular Biology, Cytogentics. Molecular Mechanisms of Growth. Animals Models in MM. Role of bone marrow microenvironment in pathogenesis of multiple myeloma. Myeloma Bone Disease. Niches within the Mutiple Myeloma bone marrow microenviriment. Novel Therapeutic Targets in MM. Monoclonal Gammopathy of Undetermined Significance. Prognostic Factors and Classification in Mutiple Myeloma. Novel Agents for Previously Untreated Mutiple Myeloma. Novel Options of Therapy- - Relapsed. High Dose Therapy in MM. Promising New Agents in phase I and II clinical trials in Multiple Myeloma. Immunotherapy in MM. Novel Therapeutic Options in Primary Systemic Amyloidosis. Novel Options of therapy in Waldenstrom Macroglobulinemia.
KENNETH C. ANDERSON is the Kraft Family Professor of Medicine, Harvard Medical School, Boston, Massachusetts; Director, Jerome Lipper Multiple Myeloma Center; and Chief, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, Massachusetts. A member of the Translational Research Working Group of the National Cancer Institute and the American Society of Clinical Oncology Translational Research Task Force, Dr. Anderson is a member of numerous societies, including the American Society for Blood and Marrow Transplantation and the American Association for Cancer Research, among other organizations. Dr. Anderson is the author, coauthor, or editor of a vast array of journal articles, book chapters, and invited lectures. Dr. Anderson received the M.D. degree from the Johns Hopkins University School of Medicine, Baltimore, Maryland.
IRENE M. GHOBRIAL is on Active Staff, Dana-Farber Cancer Institute, Boston, Massachusetts. The recipient of the ASCO Career Development Award (ASCO-CDA) (2006), Dr. Ghobrial is a member of the American Society of Hematology and the American Society of Clinical Oncology, among other organizations. Dr. Ghobrial is the author, coauthor, or editor of numerous professional publications, and received the M.D. degree from Cairo University, Egypt.